Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price on Sep 15, 2025
Y-mAbs Therapeutics Employees
Y-mAbs Therapeutics had 104 employees as of December 31, 2024. The number of employees increased by 4 or 4.00% compared to the previous year.
Employees
104
Change (1Y)
4
Growth (1Y)
4.00%
Revenue / Employee
$821,010
Profits / Employee
-$213,692
Market Cap
391.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 104 | 4 | 4.00% |
| Dec 31, 2023 | 100 | -47 | -31.97% |
| Dec 31, 2022 | 147 | -1 | -0.68% |
| Dec 31, 2021 | 148 | 23 | 18.40% |
| Dec 31, 2020 | 125 | 60 | 92.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
YMAB News
- 7 weeks ago - Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB - GlobeNewsWire
- 2 months ago - Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 2 months ago - Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB - Business Wire
- 2 months ago - Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - GlobeNewsWire
- 2 months ago - SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics - GlobeNewsWire
- 4 months ago - Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline - GlobeNewsWire
- 4 months ago - Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - GlobeNewsWire
- 5 months ago - Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript - Seeking Alpha